Recent Updates
Recently added Catalysts
MDGL Positive Sentiment Score: 70/100

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

Thursday, June 1, 2023 1 min read
Key Takeaway: Madrigal Pharmaceuticals, a clinical-stage biopharma company focusing on therapeutics for NASH, announced its participation in two significant investor conferences. The company will partake in fireside chats at the Jefferies Healthcare Conference and the Goldman Sachs Global Healthcare Conference in June 2023. These events aim to enhance investor engagement and showcase Madrigal's lead candidate, resmetirom, which targets unmet needs in liver disease. Webcasts of the discussions will be available for replay on the company's website afterward.

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal is engaged in important investor discussions to elevate its profile.
  • Participation in key healthcare conferences highlights investor interest in its pipeline.
  • Webcast availability increases transparency and accessibility for potential investors.

Full Press Release Details

CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at two upcoming investor conferences:
Jefferies Healthcare Conference
2:30 pm ET on Wednesday, June 7, 2023.
Goldman Sachs Global Healthcare Conference
12:20 pm ET on Tuesday, June 13, 2023.
The fireside chats will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Tags

Frequently Asked Questions

What is Madrigal Pharmaceuticals focused on?

Madrigal Pharmaceuticals develops novel treatments for nonalcoholic steatohepatitis (NASH).

When is the Jefferies Healthcare Conference?

The Jefferies Healthcare Conference is on June 7, 2023, at 2:30 pm ET.

What is Madrigal's lead candidate drug?

Madrigal’s lead candidate is resmetirom, an oral thyroid hormone receptor agonist.

Where can I watch the conference webcasts?

The webcasts will be available for replay on the Investors section of Madrigal's website.

When is the Goldman Sachs Healthcare Conference?

The Goldman Sachs Global Healthcare Conference is on June 13, 2023, at 12:20 pm ET.

Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals NASH investor conference resmetirom
Last updated: Jun 1, 2023